Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03343054
Recruitment Status : Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part.

The dose escalation part is open-label, and evaluates safety, preliminary efficacy and PK of single-agent talazoparib in sequential cohorts of adult patients with advanced solid tumors who are resistant to standard therapy or for whom no standard therapy is available.

In the dose escalation part, up to 18 (minimum 3) patients are expected to be enrolled depending on the observed DLTs.

The expansion part is designed to assess the efficacy, safety and PK of single-agent talazoparib at RP2D determined in the dose escalation part in adult patients with locally advanced or metastatic breast cancer who have deleterious or suspected deleterious germline BRCA1 or BRCA2 mutations.

In the expansion part, a minimum of 17 patients will be enrolled evaluable for the primary endpoint.


Condition or disease Intervention/treatment Phase
Neoplasms Breast Neoplasms Drug: talazoparib Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A PHASE 1 STUDY OF THE SAFETY, PHARMACOKINETICS AND ANTI-TUMOR ACTIVITY OF TALAZOPARIB, POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR, IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
Actual Study Start Date : November 30, 2017
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : December 28, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: talazoparib
0.75 mg/day or 1.0 mg/day
Drug: talazoparib
Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.




Primary Outcome Measures :
  1. Number of participants with Dose-limiting toxicities (DLT) [ Time Frame: Baseline up to 28 days ]
    Number of participants with Dose-limiting toxicities (DLT)

  2. Number of Participants With Objective Response [ Time Frame: Baseline up to disease progression or any case of death ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from baseline until disease progression or death due to any cause.


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, hours post-dose ]
    Maximum Observed Plasma Concentration (Cmax)

  2. Area under the Concentration-Time Curve (AUC) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

  3. Plasma Decay Half-Life (t1/2) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

  4. Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 0, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 24, 48, 72, 96, 168 hours post-dose ]
    Time to Reach Maximum Observed Plasma Concentration (Tmax)

  5. Objective Response - Number of Participants With Objective Response [ Time Frame: Baseline up to 12 months ]
    OR is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1. recorded from baseline until disease progression or death due to any cause.

  6. Pre-dose Plasma Concentration (Ctrough) [ Time Frame: 0 (pre-dose) on Day 1 of Cycle 2, 3 and 4 ]
    Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data.

  7. Time to tumor Response (TTR) [ Time Frame: From initiation of treatment up to initial objective response ]
    TTR is defined as the time from the first dose date to date of first documentation of OR.

  8. Disease Control (DC) [ Time Frame: Baseline up to disease progression or any case of death ]
    DC is defined as CR, PR or SD according to the RECIST version 1.1 recorded in the time period between first dose of study treatment and disease progression or death to any cause.

  9. Progression Free Survival (PFS) [ Time Frame: Baseline up to disease progression or any cause of death ]
    PFS is defined as the time from the first dose date to date of first documentation of PD or death due to any cause.

  10. Overall Survival (OS) [ Time Frame: Baseline up to any cause of death ]
    OS is defined as the time from the first dose date to date of death due to any cause



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

[Dose Escalation Part]

Inclusion Criteria:

  • Histological or cytological diagnosis of locally advanced or metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
  • ECOG Performance Status 0 or 1.
  • Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria:

  • Patients with known symptomatic brain metastases requiring steroids.
  • Current use of a strong P-gp inhibitor, strong P-gp inducer, or strong inhibitor of BCRP within 1 week or 5 half lives which ever is longer prior to the first dose of study treatment.
  • Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

[Dose Expansion Part]

Inclusion Criteria:

  • Histologically or cytologically confirmed carcinoma of the breast.
  • Locally advanced breast cancer that is not amenable to curative radiation or surgery and/or metastatic disease.
  • Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation by Myriad Genetics' BRACAnalysis CDx test.
  • No more than 3 prior chemotherapy-inclusive regimens for locally advanced or metastatic disease.
  • Have measurable lesion by the RECIST v.1.1.
  • ECOG Performance Status 0-2.
  • Adequate Bone Marrow, Renal and Liver Function.

Exclusion Criteria:

  • First-line locally advanced or metastatic breast cancer with no prior neoadjuvant and adjuvant chemotherapy.
  • Prior treatment with a PARP inhibitor.
  • Objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease.
  • HER2 positive breast cancer.
  • Active inflammatory breast cancer.
  • Central nervous system (CNS) metastases.
  • Current or anticipated use within 7 days prior to the first dose of study treatment, or anticipated use during the study of strong P-gp inhibitors.
  • Fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03343054


Locations
Layout table for location information
Japan
Aichi Cancer Center Hospital
Nagoya, Aichi, Japan, 464-8681
National Cancer Center Hospital East
Kashiwa, Chiba, Japan, 277-8577
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, Japan, 003-0804
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan, 241-8515
Saitama Cancer Center
Kitaadachi-gun, Saitama, Japan, 362-0806
National Cancer Center Hospital
Chuo-Ku, Tokyo, Japan, 104-0045
Hakuaikai Medical Corporation Sagara Hospital
Kagoshima, Japan, 892-0833
National Hospital Organization Osaka National Hospital
Osaka, Japan, 540-0006
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03343054    
Other Study ID Numbers: C3441030
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: July 21, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Phase 1
talazoparib
PF-06944076
MDV3800
BMN673
PARP inhibitor
Japanese
solid tumors
breast cancer
C3441030
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents